$SPRB
相关推文
按时间倒序
-
博主分享在SPRB上2小时获利3.7万美元并部分止盈的经历。
我无语了……在 $SPRB 上2小时内赚了+$37K（已实现+$21K）。最终我止盈了大部分仓位。 对我来说这不算多，但鉴于如此短的时间框架，我觉得这很有趣，只是没人可以分享。 我会持有价值$30k的仓位看看后续走势。https://t.co/ywK3ozncPA
英文原文
I have no words… +$37K on $SPRB in 2 hours ($21K realized). Ended up taking profit on most. It’s not much to me but I just find this amusing given the short timeframe and had nobody to share it with. I’ll hold $30k worth to see where it goes. https://t.co/ywK3ozncPA
-
分析NBIS、AMZN、SNAP等个股机会，看好AI基建及降息预期。
10月6日周一收盘思考： - $NBIS 是极好的逢低买入机会。早盘上涨5.78%后回落2.38%。从 $IREN 到 $CIFR 的所有其他新云(Neoclouds)公司都守住了4%-14%+的涨幅。Nebius可能受期权资金流影响，预计很快会补涨，我维持 $225 的目标价(PT)。 - $AMZN, $META 是两只在未来2-3个月应跑赢大盘并补涨的七巨头(Mag7)成员。尤其是亚马逊。 - $SNAP, $RDDT 是两个不错的反弹标的。Snapchat尤其因为收入变现模式的改变。如果你有耐心持有股票一两年，我预期会有50%+的回报，只是取决于市场何时将其定价。并非每个人都有耐心，且将资金用于 $SNAP 而非新云(Neoclouds)的机会成本可能不划算。 关于Reddit，我一直认为ChatGPT引用是其暴跌29%的借口，所以我已买入。 - $SPRB 吸引了所有人的注意。我预计它将从7500万美元市值继续上涨至1.5亿-2亿美元，但这就像玩俄罗斯轮盘赌，通常在重大事件后2-3天就会发生稀释。 - 像 $RKLB 这样的股票，只需持有哈哈。即使它是我最高信用的5年期长线标的，也确实高估了，但此时它可能会像 $PLTR 一样表现。 - $AMD 与 OpenAI 的交易对半导体行业极度利好。我预计 $TSM, $ASML, 能源股和新云(Neoclouds)将从AI基础设施建设中受益。主要的负面因素是 $CRWV，因为其对 $NVDA 的依赖，以及显然的NVDA本身，但新云(Neoclouds)并未锁定单一玩家，且已锁定5-10年以上的合同。 这仅对 $NVDA 的护城河理念造成微小影响，但尚无实质性影响。 我个人认为AMD可能会像 $ORCL 一样在反弹后回调，然后当市场开始计入远期收入时，像 $AVGO 一样表现。 话说回来，我不知道OpenAI从哪弄来这么多钱，承诺给Oracle、AMD等这些十亿或百亿美元的交易，如果它们估值只有5000亿的话哈哈。 - 黄金每天创历史新高，仅仅表明 $BTC 始终是好的买入标的，即使在 $123k，如果它最终成为对抗通胀的对冲工具。其市值约为黄金的1/10。 - $LTC 仍然是很好的买入标的，因为ETF获批。由于政府停摆，人们只是忘记了它尚未发生，但最终应该会获批。 - $VIRT 在 $32.5 是极好的买入，我会在这个区间进行成本平均（抱歉如果你在 $36 买了看涨期权，我的仓位下跌了约35%）。但再次强调，这是对VIX的非对称对冲（VIX隐含波动率很高用于对冲，VIRT被低估~6.3倍远期市盈率，有回购和低隐含波动率），所以即使仓位下跌，你的其他股票应该会上涨以平衡。 - 仍在研究其他受益于基础设施建设的能源股、小盘股如 $EOSE、存储如 $MU 等，这些是粉丝推荐的。我尽量不在自己充分了解前谈论太多。 - 如果你使用杠杆或做多，现在是时候了，直到一月。三次降息，市场可能正在提前交易十月的降息。
英文原文
Monday October 6th Market Close Thoughts: - $NBIS extremely good dip buy. Down 2.38% after rising 5.78% in the morning. All other Neoclouds from $IREN to $CIFR held their 4%-14%+ gains. Nebius likely influenced by option flow, should play catchup soon and I stand by $225 PT. - $AMZN, $META two Mag7 that should outperform next 2-3 months and play catchup with the rest. Especially Amazon. - $SNAP, $RDDT two good recovery plays. Snapchat especially because of the revenue monetization changes. If you have the patience for shares for a year or two, I'd expect a 50%+ return, just whenever the market wants to price it in. Not everyone has patience and opportunity cost using the funds in $SNAP instead of Neoclouds might not be worth. Reddit I've maintained that the citations from ChatGPT is a BS reason for a 29% sell-off so I bought into it. - $SPRB caught everyone's attention. I do expect it to keep rising to a $150-$200m marketcap from $75m but it's like playing Russian Roulette, usually dilution happens 2-3 days after a major event. - Stuff like $RKLB, just need to hold lol. It's genuinely overvalued even if it's highest conviction 5Y long but at this point it might pull a $PLTR. - $AMD x OpenAI deal heavily bullish for semi industry. I expected $TSM, $ASML, energy stocks and Neoclouds to get a boost from AI infra buildout. Main negative ones were $CRWV, because of $NVDA dependencies and obviously NVDA, but Neoclouds aren't locked into one player, and they already have 5-10+ year contracts locked in. It just puts a tiny dent in the $NVDA moat idea but nothing material yet. I personally think AMD might pull an $ORCL where it dips past rally, and then ends up pulling an $AVGO when markets start pricing in forward revenue. Then again, I don't know where OpenAI is getting all this money to promise Oracle, AMD, etc. all these ten or hundred billion dollar deals if they're valued at 500B lol. - Gold rallying to ATH every day just signals that $BTC is always a good buy, even at $123k, if it ends up becoming a hedge against inflation. It's close to 1/10th the market-cap. - $LTC still a great buy because of ETF approval. There's the government shutdown so people just forgot it hasn't happened yet, but should get approved eventually. - $VIRT great buy at $32.5, I'd cost average around this range (sorry if you bought calls at $36, my positions are down 35% or so). But again it's an asymmetrical hedge to VIX (VIX IV very high for hedging, VIRT is undervalued ~6.3 forward p/e with buybacks an low IV), so even if positions are down, your other stocks should go up to balance it out. - Still looking into other beneficiaries of buildouts from energy stocks, small caps like $EOSE, memory like $MU, etc. that followers recommended. I try not to talk about something much until I'm informed myself. - If you're on leverage or going long, now is the time to do it until January. 3x rate cut, market probably frontrunning Oct rate cut now.
-
分析SPRB估值与稀释风险，虽短期或涨至$500，但不建议长期持有。
TLDR：如果没有稀释，仅因TA-ERT催化剂，股价可能暂时涨至$500。但这在稀释日如同玩俄罗斯轮盘赌。 我花更多时间研究了细节： $SPRB 的合理市值约为1.5亿-2亿美元（目前8500万）。原帖作者声称目标价$500，若公司不稀释则合理。 然而： 截至2025年6月30日，SPRB现金等价物仅1640万美元，鉴于现金余额低，通过增发新股进行稀释似乎不可避免。股价上涨源于低流通盘+利好消息（无16%这样的空头头寸，故非空头挤压）。 增发新股+稀释后（市值1.5亿-2亿美元可能使股价回归~$50-75），若计入稀释，我不认为能看到$500的目标价。 我们可能会因流通盘有限看到另一波100%+的上涨冲向$500（就像$BULL因低流通盘涨至600亿市值那样），但由于随机日期的稀释如同俄罗斯轮盘赌，我不建议长期持有。 无论如何，我喜欢玩俄罗斯轮盘赌。欢迎任何反驳观点。
英文原文
TLDR: Might go up to $500 temporary strike if there's no dilution just because of TA-ERT catalyst. But it's playing Russian Roulette on dilution days. So had some more time to look into things: Fair value $SPRB market cap is = ~$150–200m. ($85M now). In OP's post they claimed $500 PT, which is fair if company doesn't dilute. However: SPRB has $16.4M in cash equivalents, June 30, 2025, dilution with new shares seems inevitable just because of low cahs balance. Price rise was due to low float + good news (there's no short interest like .16% so not a short squeeze) After issuing new shares + dilution (Market cap at $150m-$200m might normalize share price to ~$50-75), don't really see the $500 figure if dilution is included. We might see another 100%+ runup just because of limited float toward that $500 mark (like how $BULL ran to a $60B MC off low float), but I would be against holding it long term because of russian roulette dilution on a random day. Either way, I like playing Russian Roulette. Welcome any counterpoints
-
博主澄清仅众包收集SPRB信息，非发表观点，自称不懂生物技术。
@tr90605549 我只是想通过众包方式收集关于 $SPRB 的信息以深入学习，并非要分享方向性观点。我对生物技术(biotech)领域真的完全不了解。
英文原文
@tr90605549 Oh I’m just trying to crowdsource information on $SPRB to learn more, not share a directional opinion. I genuinely have zero clue about biotech.
-
分析SPRB酶替代疗法获批后的市值潜力，自曝买入并求教。
在 @MartinShkreli 发帖后，我查看了 $SPRB，它涉及 TA-ERT（酶替代疗法），属于突破性疗法。 粗略估算，如果 SPRB 的 TA-ERT 获批并长期占据 10-15% 的市场份额（对应 1.8 亿-2.7 亿美元 ARR），基于 14 亿美元的美国市场... 通过 2-3 倍营收计算，当前合理的公允价值可能在 2.8 亿-6.3 亿美元市值之间。 当然，从临床试验失败、商业化到稀释风险都很大，但 8500 万美元的市值看起来很有潜力？ （披露：我买了 5 万美元，纯粹作为高风险博弈） 显然我不是生物技术专家，这超出了我的专业领域，所以我想看看是否有其他领域专家能提供反馈或指出红旗警示。
英文原文
I was looking at $SPRB after @MartinShkreli posted about it and it’s TA-ERT, breakthrough enzyme therapy replacement. Just from a quick search if SPRB’s TA-ERT is approved and they capture 10-15% market share longer term ($180–$270M ARR) of $1.4B US market... Realistic fair value today could be ~$280m-630m MC from 2-3x rev calculations. Obviously there’s a lot of risk from clinical failures, commercialization, to dilution but a $85M market cap looks promising? (disclosure I bought $50k worth just as a high risk gamble) Obviously I’m not an expert in biotech and this is outside my domain, which is why I wanted to see if anyone else with any domain knowledge had feedback or red flags.